menu
    • menu
    [{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Williamsburg Venture Holdings","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Nephrology","graph2":"Phase II","graph3":"ZyVersa Therapeutics, Inc","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"ZyVersa Therapeutics, Inc \/ Williamsburg Venture Holdings","highestDevelopmentStatusID":"8","companyTruncated":"ZyVersa Therapeutics, Inc \/ Williamsburg Venture Holdings"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Nephrology","graph2":"Phase II","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ZyVersa Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ZyVersa Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Larkspur Health Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Nephrology","graph2":"Phase II","graph3":"ZyVersa Therapeutics, Inc","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.01,"dosageForm":"Intravenous Injection","sponsorNew":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition Corp."},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Larkspur Health Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Nephrology","graph2":"Phase II","graph3":"ZyVersa Therapeutics, Inc","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.01,"dosageForm":"Intravenous Injection","sponsorNew":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition Corp."},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"George Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Nephrology","graph2":"Phase II","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ZyVersa Therapeutics, Inc \/ George Clinical","highestDevelopmentStatusID":"8","companyTruncated":"ZyVersa Therapeutics, Inc \/ George Clinical"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Nephrology","graph2":"Phase II","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ZyVersa Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ZyVersa Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Larkspur Health Acquisition Corp","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IC 100","moa":"ASC","graph1":"Neurology","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition Corp","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition Corp"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"University of Miami","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Funding","leadProduct":"IC 100","moa":"ASC","graph1":"Neurology","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ZyVersa Therapeutics, Inc \/ University of Miami","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Therapeutics, Inc \/ University of Miami"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"2-hydroxylpropyl-beta-cyclodextrin","moa":"Cholesterol","graph1":"Nephrology","graph2":"Phase II","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ZyVersa Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ZyVersa Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"IC 100","moa":"ASC","graph1":"Neurology","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ZyVersa Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"IC 100","moa":"ASC","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ZyVersa Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IC 100","moa":"ASC","graph1":"Neurology","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ZyVersa Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Larkspur Health Acquisition Corp.","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IC 100","moa":"ASC","graph1":"Neurology","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition Corp.","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition Corp."},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Private Placement","leadProduct":"IC-100-08","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ZyVersa Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Large Molecule","year":"2025","type":"Inapplicable","leadProduct":"IC-100-08","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ZyVersa Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Therapeutics, Inc \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by ZyVersa Therapeutics, Inc

    Menu

    ZyVersa Therapeutics, Inc

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Williamsburg Venture Holdings

                            Deal Size : $10.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            ZyVersa Announces Share Purchase Agreement Partnership with Williamsburg Venture

                            Details : The proceeds will be used to advance clinical development of VAR 200 in development for treatment of chronic kidney diseases.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 25, 2025

                            Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Williamsburg Venture Holdings

                            Deal Size : $10.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IC-100-08

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ZyVersa Shows Promise Using Inflammasome & GLP-1 Combo for Obesity Needs

                            Details : IC 100 is an inflammasome ASC Inhibitor, which is currently under development for the treatment of obesity.

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            May 07, 2025

                            Lead Product(s) : IC-100-08

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IC 100

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ZyVersa Data Shows Inflammasome Inhibition Lowers Neuroinflammation in Alzheimer’s

                            Details : IC 100 is a NLRP3-inflammasome inhibitor, small molecule drug candidate, which is currently being evaluated for the treatment of alzheimer’s disease.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            March 12, 2025

                            Lead Product(s) : IC 100

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IC 100

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ZyVersa's NLRP3 Inhibitor Shows Heart, Glucose Benefits in Obese Models

                            Details : MCC950 is a NLRP3-inflammasome inhibitor, small molecule drug candidate, which is currently being evaluated for the treatment of heart failure (HFpEF) and type 2 diabetes.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            March 05, 2025

                            Lead Product(s) : IC 100

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2-hydroxylpropyl-beta-cyclodextrin

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 05, 2024

                            Lead Product(s) : 2-hydroxylpropyl-beta-cyclodextrin

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ZyVersa Gets IRB Approval for Phase 2a Trial Of VAR 200 in Diabetic Kidney Disease

                            Details : VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is being developed to mediate removal of excess cholesterol that damages the kidneys’ filtration system in patients with Diabetic Kidney Disease.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 18, 2024

                            Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IC-100-08

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $2.7 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            ZyVersa Raises $2.7M as Inflammasome Inhibitors Show Promise for Obesity Treatment

                            Details : The net proceeds will be used to focus on the clinical development of IC 100-08, a novel humanized IgG4 monoclonal antibody. Currently, it is being evaluated in the preclinical studies for obesity.

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            February 29, 2024

                            Lead Product(s) : IC-100-08

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $2.7 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Sponsor : George Clinical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator...

                            Details : VAR 200 (2-hydroxypropyl-beta-cyclodextrin, 2HPβCD) is a phase 2a-ready drug in development which has potential to treat multiple kidney diseases, including diabetic kidney disease, rare kidney diseases, FSGS (focal segmental glomerulosclerosis) and Alp...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 14, 2023

                            Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Sponsor : George Clinical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ZyVersa Therapeutics Adds Two Esteemed Leaders in Nephrology to Its Renal Scientific Advisory Board to Support...

                            Details : VAR 200 (2HPβCD) is a cholesterol efflux mediator in development to ameliorate renal lipid accumulation that damages the kidneys' filtration system. VAR 200 passively and actively removes excess lipids from the kidney and has potential to treat other gl...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 01, 2023

                            Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Larkspur Health Acquisition Corp.

                            Deal Size : $10.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            ZyVersa Therapeutics and Larkspur Health Acquisition Corp. Announce Business Combination, Interim Financing an...

                            Details : The support will enable company to advance clinical evaluation of cholesterol efflux mediator candidate (VAR 200) in patients with orphan renal disease, FSGS, and to progress the inflammasome ASC inhibitor candidate (IC 100) into Phase 1 trials.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 27, 2022

                            Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Larkspur Health Acquisition Corp.

                            Deal Size : $10.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth